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Abstract
Background: Research in rare genetic syndromes associated with ASD is often hampered by the wide geographic
distribution of families and the presence of medical comorbidities, such as epilepsy, that may preclude travel to
clinical sites. These challenges can limit the sample size and generalizability of the cohorts included in both natural
history studies and clinical trials. Tuberous sclerosis complex (TSC) is a rare genetic syndrome that confers an
elevated risk for autism spectrum disorder (ASD), with social communication delays identified in this population as
early as 12 months of age. Early identification of risk necessitates parallel testing of early intervention, prompting
the first randomized controlled clinical trial of behavioral intervention for infants with TSC (NCT03422367). However,
considerable early recruitment challenges have mandated the systematic identification of enrollment barriers
followed by modification of the study design to address these barriers.
Methods: Caregivers were interviewed regarding barriers to enrollment (phase 1). Adaptations to the intervention
were made to address these barriers (phase 2). Outcomes based on this modification to the study design were
defined by enrollment rate and participant demographics.
Results: Qualitative reports from caregivers indicated that distance and time were the primary barriers to clinical
trial enrollment. The intervention was then modified to a remote model, with at-home, parent-delivered
intervention, and weekly video conferencing with interventionists at the study sites. Enrollment increased 10-fold
(from 3 to 30 participants) within 1 year and included a more diverse and clinically representative cohort of infants.
Conclusion: The design and implementation of more scalable methods to disseminate research remotely can
substantially improve access to clinical trials in rare neurodevelopmental disorders. The lessons learned from this
trial can serve as a model for future studies not only in rare conditions, but in other populations that lack adequate
access, such as families with limited financial or clinical resources. Continued efforts will further refine delivery
methods to enhance efficiency and ease of these delivery systems for families.
Keywords: Telehealth, Early intervention, Tuberous sclerosis complex, Clinical trial recruitment, Behavioral
intervention, Autism spectrum disorder, Remote delivery
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Background
Over the last decade, a host of identified genetic etiolo-
gies associated with autism spectrum disorder (ASD)
have helped to disentangle the vast heterogeneity of the
condition and inform more targeted treatments. Each of
these genetic syndromes is rare (with prevalence rates
ranging from 1/50,000 to 1/6000), but together they ac-
count for up to 15% of ASD [1]. Children with “syn-
dromic” autism share common clinical features,
including varying degrees of co-occurring conditions
such as intellectual disability, motor impairment, epi-
lepsy, sleep problems, and gastrointestinal dysfunction,
necessitating timely treatments. Many of these syn-
dromes manifest in infancy, with epilepsy or other med-
ical comorbidities emerging well before an ASD
diagnosis can be made. This early identification opens
the door for preemptive interventions that might change
developmental trajectories and improve outcomes. How-
ever, studies are challenged by the wide geographic dis-
tribution of families and the presence of medical
comorbidities that may preclude travel to clinical sites.
These challenges can limit the sample size and
generalizability of the cohorts included in both natural
history studies and clinical trials [2, 3]. More scalable
methods to disseminate research remotely to individuals
with rare disorders are urgently needed. Once developed,
these methods can translate to other populations that
lack adequate access, such as families with limited
financial or clinical resources [4–6].
Here, we describe our experience with barriers to ac-
cess during an ongoing clinical trial for behavioral inter-
vention in infants with Tuberous Sclerosis Complex and
the subsequent strategies formulated to mitigate the im-
pact of these barriers. Tuberous sclerosis complex (TSC)
is a rare autosomal dominant disorder caused by muta-
tions in the TSC1 or TSC2 gene, occurring in 1 in
7000–13,000 children [7]. TSC is highly penetrant for
ASD, with diagnostic rates approaching 60% (compared
to up to 2% in the general population) [8–10]. Moreover,
because TSC is often diagnosed in utero [11, 12], these
infants can be monitored for signs of atypical develop-
ment well before a clinical ASD diagnosis is made. In a
previous longitudinal study of early development, we
found that infants with TSC who developed ASD dem-
onstrated marked social communication and nonverbal
cognitive delays by age 12 months [13, 14], with deficits
in nonverbal communication skills such as eye contact,
coordination of gaze, engagement, and social referen-
cing. Despite these clear behavioral markers of atypical
development in early infancy, most infants in this study
were not receiving targeted social communication inter-
ventions, with therapeutic effort focused instead on glo-
bal development (such as physical therapy to address
delayed motor skills).
These natural history study findings prompted the de-
sign of a clinical trial of early behavioral intervention tar-
geting social communication skills, with the ultimate
goal of improving developmental outcomes. To target
the specific nonverbal communicative delays identified
in our longitudinal study, a behavioral intervention
known as JASPER (Joint Attention, Symbolic Play,
Engagement and Regulation) was selected. JASPER has
been rigorously studied through clinical trials and has
been shown to improve social communication and
language skills in toddlers showing red flags for ASD
[15]. The clinical trial, called JETS (JASPER Early Inter-
vention in Tuberous Sclerosis, NCT03422367), fills a
critical gap in treatment studies in TSC and is the first
randomized clinical trial of early behavioral intervention
for this syndrome.
There were high expectations that the target enrollment
of 60 infants across two study sites would be readily
achieved. The initial study included a waitlist-control de-
sign (see Fig. 1), with 12 weekly in-person visits over a 3-
month active intervention period to one of the two study
sites (Los Angeles and Boston) for parent-education based
behavioral intervention. Comprehensive in-person assess-
ments were to be performed across four additional time
points: pre-intervention, post-intervention, 6-month
follow-up, and a 1-year follow-up. However, after one full
year of the study, despite active national recruitment ef-
forts supported by the TSC patient alliance group (Tuber-
ous Sclerosis Alliance) and local TSC clinics, only 3
infants were enrolled.
In response to this recruitment challenge, a two-phase
process was undertaken to (1) identify the barriers faced
by interested families who decided not to enroll and
then to (2) make modifications to the study design based
upon these findings. Data from parent interviews on bar-
riers to enrollment (phase 1) informed changes made to
the research design to improve access (phase 2).
Changes in enrollment rate and parent perception fol-
lowing the study design modifications motivate a discus-
sion about the implications of this type of remote
delivery for improved access in clinical trials across neu-
rodevelopmental disorders.
Phase 1: barrier identification
Methods
Recruitment
Recruitment of infants with TSC between 12 and 36
months for the clinical trial was attempted through a
variety of well-established mechanisms: TSC specialty
clinics, National TS Alliance referrals, online social
media postings, and institution-specific medical record
queries. Eligible infants had a clinical diagnosis of TSC,
with the only exclusion being a planned epilepsy surgery
during the trial period.
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Screening interview
All caregivers who responded to an advertisement or
physician/alliance referral (n = 25) were contacted via
phone. To screen infants for eligibility, caregivers were
asked about the age of the child, their clinical diagnosis
of TSC, and any upcoming epilepsy surgeries. All 25 of
the contacted participants screened as eligible. Staff ex-
plained study details and answered questions about par-
ticipation. Caregivers were then asked whether they
would like to enroll in the study, either immediately fol-
lowing screening or after several days if parents re-
quested time to consider.
Barriers to enrollment
Twenty-two of 25 caregivers chose not to enroll follow-
ing the informational screening. These 22 families were
asked two open-ended questions regarding their deci-
sion: (1) “What were the factors that led to your decision
to not enroll in the study?” (2) “Are you interested in fu-
ture contact if other enrollment options become avail-
able?” The results from these interviews were
transcribed and categorized.
Collection of demographics
Caregivers who enrolled in the study completed a demo-
graphics questionnaire at entry, providing information
about income, race and ethnicity, and education level.
Results
Barrier identification
The enrollment yield for the in-person trial design was
12%. Interviews with parents who did not enroll yielded
responses that fell into one of two categories, both indi-
cating logistical challenges. The first barrier was time
(27%), which included responses related to work sched-
ules, availability of a secondary caregiver, and frequency
of appointments; the second barrier was distance (72%)
which included responses related to concern for travel
costs and flying with their child (see Fig. 2). None of the
responses indicated a lack of study buy-in or perceived
importance of the research. All families agreed to be
recontacted and many expressed a desire to participate
under alternate circumstances. For example, one care-
giver stated “We are extremely disappointed and hope
that another trial will come up for my little one,” and
another commented, “If virtual ever becomes an option,
we’d be interested.”
Phase 2: addressing barriers
Methods
Overview of remote caregiver training model
After identifying consistent challenges in recruiting fam-
ilies for participation in weekly in-person intervention
sessions, a remote delivery method of intervention was
developed to decrease demands of time and travel. The
new model (Fig. 1) represents an adaptation of an exist-
ing protocol being used by Kasari et al. to remotely train
JASPER interventionists nationally and internationally,
with the modifications made to train caregivers [15–18].
The protocol includes teaching intervention skills and
presenting curriculum content by video conference, ask-
ing trainees to practice their newly acquired techniques
and to record one of the practice sessions, and submit-
ting videos for review by a training team at one of the
study sites [18]. All weekly questionnaires were digita-
lized. To accommodate this model for caregiver training,
the study team consulted with the Security Compliance
Office to identify secure and HIPAA-compliant plat-
forms for intervention delivery, resulting in an Institu-
tional Review Board (IRB) approved protocol. The
original study design required weekly travel for 100% of
sessions, while in the modified design, 70% of sessions
Fig. 1 Modified intervention design
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are completed remotely. This change reduced the num-
ber of in-person hours (assessments, live intervention
sessions, and questionnaires) from 33 to 19 and the total
number of participation hours (including video confer-
ence sessions and online questionnaires) from 39 to 30.
Financial reimbursement was moderately increased from
$40 to $140, with one night of lodging provided to fam-
ilies at a hotel near the study sites. Families were re-
ferred to private funding sources such as National
Organization for Rare Disorders (NORD) for further
reimbursement.
Detailed protocol of caregiver training model
Under the new model, caregivers first attended an in-
clinic intervention session focused on active coaching,
live demonstration, and direct feedback. Caregivers then
received an encrypted tablet to use for the duration of
the intervention, with detailed operation instructions
and a live demonstration. Caregivers returned home
with the goal of practicing JASPER strategies daily. An
automated text messaging tool allowed caregivers to eas-
ily report their intervention practice time on a daily basis
by responding to nightly text. Once per week, caregivers
recorded a 30-min practice video on the tablet and
uploaded it to a private and secure server. After the
weekly upload, a trained interventionist at one of the
study sites reviewed the video. Then, during a 30–60
min weekly video conference with the caregiver, the JAS-
PER interventionist provided feedback and introduced
new JASPER content for the following week. Content
built weekly to introduce new strategies and increase
complexity (based on intervention presented in [16]).
Weeks 1, 5, 9, and 12 (4 total) took place in-clinic; weeks
2, 3, 4, 6, 7, 8, 10, and 11 (8 total) took place remotely.
To collect data on parent fidelity and perspectives, care-
givers and interventionists completed weekly question-
naires online through an internal institutional database.
Two of these sessions (1 and 12) were combined with
visits to study sites for in-person assessments to further
reduce travel and scheduling burden on families.
Following these modifications, all 22 previously inter-
ested families were recontacted with the option to enroll
in the remote intervention model. New families were
also contacted for enrollment. Caregivers who chose not
to enroll were administered the qualitative interview re-
garding their decision.
Fig. 2 Map of participants with enrollment status and breakdown of enrollment barriers for original design (1a and 1b) and remote design (2a
and 2b); Total number of participants enrolled in study with original and remote design (3)
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Results
Six months after the modification to remote delivery,
half of the recontacted participants (11/22) enrolled in
the study, with the remaining caregivers continuing to
cite distance (45%) or time (54%) as barriers to enroll-
ment. Within 1 year of the intervention modification, 23
new families expressed interest, resulting in the enroll-
ment yield increasing to 82% for newly contacted partici-
pants (19/23). The four new caregivers who expressed
interest in the study but were ultimately unable to enroll
identified their primary barrier for enrollment as either
time (25%), distance (50%), or medical instability due to
epilepsy (25%) as the primary barrier.
Although the sample size of the initial cohort was very
small (n = 3) compared to the expanded cohort (n = 30),
a comparison of the two cohorts for descriptive purposes
was performed, indicating that the new cohort included
a more diverse and representative sample of participants.
The percentage of families earning < $90,000 per year in-
creased from 0 to 23%, the percentage of families identi-
fied as non-white increased from 0 to 33%, and the
percentage of parents without a college degree increased
from 0 to 27%. Additionally, the average distance of the
participants from the research site increased from 42 to
320 miles, demonstrating the improved geographical
reach attained by the modified remote intervention. Fol-
lowing enrollment in the study, a caregiver stated “We
live in a rural area where no one has heard of TSC, so it
is great to be able to talk to the experts and know they
have an eye on my child! I love being able to learn and
add to my parent toolbox from my own home, and know
I can practice these skills with her every day,” while an-
other said, “We decided when we got the diagnosis that
we would do anything and go anywhere to help our son,
but doing the intervention at home has been made our
participation so much more manageable. I tell every par-
ent I meet that this is a must-do.”
Discussion
Here, we describe a rapid acceleration in clinical trial en-
rollment accomplished by the deployment of a remote
intervention and assessment strategy. This modification
of trial design was necessitated by barriers to access that
precluded initial patient enrollment of an already funded
clinical trial. Although we did not set out to systematic-
ally compare different strategies for enhanced enroll-
ment, the narrative provided here introduces critical
themes around enrollment barriers and remote delivery
methods that are not unique to TSC. There is a high un-
met need for treatment studies in rare neurodevelop-
mental disorders, yet challenges raised by the
geographical distribution and the complex medical needs
of these individuals often hamper effective recruitment
and study success. The cost to participate in research,
particularly intervention, is not only financial (lodging,
airfare, meals) but also psychosocial, with disruption of
routines and schedules, absence from home and work,
and added caregiver burden. Study participation often
requires caregivers to commit time during weekdays, re-
quiring flexibility of employment hours, additional child-
care, and availability of secondary caregivers. Other
clinical trials for rare neurodevelopmental disorders have
also begun to use remote intervention strategies, includ-
ing the NeuroNext trial for Fragile X Syndrome
(NCT02920892), which provides language intervention
in conjunction with pharmacotherapy through a com-
bination of clinic visits and at-home synchronous video
conferencing sessions. Telehealth has additionally bene-
fitted clinical care through models such as a hub and
spoke network delivery system in which an anchor “hub”
provides comprehensive expertise to secondary “spokes”,
including local healthcare providers [19]. One such
model known as the Extension for Community Health-
care Outcomes (ECHO) has been applied to Phelan-
McDermid Syndrome [20] and provides a platform for
video-consultation between local physicians and aca-
demic experts to support clinical care in communities,
thereby reducing the burden of care on both healthcare
providers and caregivers. These telehealth models may
prove effective in addressing challenges in recruitment
for clinical trials, and importantly, disseminating aca-
demic expertise and evidence-based intervention to
communities.
There are certainly limitations to remote delivery, in-
cluding the potential for compromised standardization
of protocols, reduced commitment to participation due
to the lack of personal contact with study staff, and vari-
able access to and comfort with technology for care-
givers. More technological sophistication could further
streamline and simplify the process for families, such as
the use of a single cell phone application for data collec-
tion and intervention, or the replacement of all in-
person visits with remote assessment tools. Varying
doses of remote delivery need to be tested to determine
the minimum amount of live interaction required to
achieve measurable outcomes of interest.
Our remote adaptation of intervention directly ad-
dresses the barrier of distance, thus greatly increasing
enrollment in the study from a geographically diverse
pool of participants. Descriptively, the remote interven-
tion cohort is also more representative than the small
in-person cohort (a higher percentage of non-white and
non-college educated caregivers); however, due to fund-
ing restrictions, the financial burden of travel was not
fully addressed, and this barrier continues to limit the
socioeconomic diversity of participants. In addition,
there may be an inherent recruitment bias in the families
that chose to engage in remote intervention, possibly
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selecting for families of infants that are more severely af-
fected by comorbidities, lack financial resources, have
limited access to clinically recommended early interven-
tion programs, or live farther from TSC centers of excel-
lence. One might argue that the subset of families who
chose to enroll may not represent the broader TSC pa-
tient population due to selection factors, thus influen-
cing the generalizability of this type of remote
intervention delivery. To address this possible bias, we
might consider the subgroup of families who were ini-
tially contacted for in-person intervention and then
recontacted after modification. Of these families, 10%
enrolled in the in-person intervention and 50% elected
to participate when a remote option was made available,
a lower proportion than the subsequent 82% that en-
rolled upon first contact. We did not collect demo-
graphic or clinical information on the infants that did
not enroll, but this distinction does suggest inherent dif-
ferences in cohorts based on study design and delivery
methods that need to be considered when clinical out-
comes are determined.
This study represents an important effort to increase
access to intervention clinical trials, which will continue
to remain the fundamental obstacle in treatment of rare
neurodevelopmental disorders. The paradigm must shift
from considering the “gold standard” as research con-
ducted in academic centers to studies that promote
family-centered, home-based delivery that maximize par-
ticipation of all affected children. We also must
emphasize that the data presented here are descriptive
and meant to generate discussion around the need for
innovation in trial design and delivery to maximize ac-
cess and participation in rare neurodevelopmental disor-
ders. From this experience, we may not be able to
conclude that this particular remote delivery strategy is
more effective for recruitment than alternative methods,
such as the provision of in-home sessions with interven-
tionists, web-based information delivery, or direct re-
cruitment and intervention delivery that coincide with
clinic appointments. A critical future direction will be to
directly compare enrollment achieved through these
various strategies.
Conclusion
Modification of this clinical trial to include remote deliv-
ery of intervention enhanced enrollment tenfold within
1 year and greatly improved the geographic and socio-
economic reach of the study. The striking, rapid surge in
enrollment with these adjustments reinforces the tre-
mendous motivation of these families to participate in
clinical trials, as well as the need for behavioral interven-
tion and rigorous testing of new approaches to enhance
access to research in rare neurodevelopmental disorders.
This telehealth model can facilitate future studies not
only in rare conditions, but also in other populations
that lack adequate access, such as families with limited
financial or clinical resources. This study represents an
important step towards building an evidence base for re-
mote strategies to promote scalable access to interven-
tion for children with rare genetic disorders, and it
reveals a critical direction for future research inquiry as
we identify which delivery methods are most effective
for diverse populations.
Abbreviations
ASD: Autism spectrum disorder; ECHO: Extension for Community Healthcare
Outcomes; IRB: Institutional Review Board; JASPER: Joint Attention, Symbolic
Play, Engagement and Regulation; JETS: JASPER Early Intervention for




CH collected and analyzed recruitment data and implemented methods
adaptations and was a major contributor in writing the manuscript. MP, NM,
and SJ were major contributors in writing the manuscript. All authors read
and approved the final manuscript.
Funding
This study is funded by an R01 award from NIH, NCT03422367.
Availability of data and materials
The datasets generated and/or analyzed during the current study will be
available in the NDAR repository upon completion of study.
Ethics approval and consent to participate
Families who enrolled in the study signed informed consent for usage and
storage of de-identified data. This study was approved by the UCLA Medical




The authors declare that they have no competing interests.
Author details
1UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles,
CA 90095, USA. 2UCLA Graduate School of Education and Information
Studies, Los Angeles, CA 90095, USA. 3UCLA Semel Institute, Los Angeles, CA
90095, USA. 4Boston Children’s Hospital and Harvard Medical School, Harvard
Graduate School of Education, Boston, MA 02115, USA. 5Massachusetts
General Hospital and Harvard Medical School, Herscot Center for Tuberous
Sclerosis Complex, Boston, MA 02114, USA.
Received: 6 September 2019 Accepted: 13 December 2019
References
1. Geschwind DH. Genetics of autism spectrum disorders. Trends Cogn Sci.
2011;15(9):409–16. https://doi.org/10.1016/j.tics.2011.07.003.
2. de la Paz MP, Villaverde-Hueso A, Alonso V, János S, Zurriaga O, Pollán M,
Abaitua-Borda I. Rare diseases epidemiology research. Adv Exp Med Biol.
2010;686:17–39. https://doi.org/10.1007/978-90-481-9485-8_2.
3. Davis SA, Feldman SR. Using Hawthorne Effects to Improve Adherence in
Clinical Practice: Lessons From Clinical Trials. JAMA Dermatol. 2013;149(4):
490–1. https://doi.org/10.1001/jamadermatol.2013.2843.
4. Carr T, Lord C. A pilot study promoting participation of families with limited
resources in early autism intervention. Res Autism Spectr Disord. 2016;25:
87–96. https://doi.org/10.1016/j.rasd.2016.02.003.
5. Lord C, Bishop SL. Autism spectrum disorders: diagnosis, prevalence, and
services for children and families. Soc Policy Rep. 2010;24(2) Retrieved from




6. Tek S, Landa RJ. Differences in autism symptoms between minority and
non-minority toddlers. J Autism Dev Disord. 2012;42(9):1967–73. https://doi.
org/10.1007/s10803-012-1445-8.
7. Ebrahimi-Fakhari D, Mann LL, Poryo M. Incidence of tuberous sclerosis and
age at first diagnosis: new data and emerging trends from a national,
prospective surveillance study. Orphanet J Rare Dis. 2018;13:117. https://doi.
org/10.1186/s13023-018-0870-y.
8. Baio J, Wiggins L, Christensen DL, et al. Prevalence of Autism Spectrum
Disorder Among Children Aged 8 Years — Autism and Developmental
Disabilities Monitoring Network, 11 Sites, United States. MMWR Surveill
Summ 2018. 2014;67(SS-6):1–23. https://doi.org/10.15585/mmwr.ss6706a1.
9. Asano E, Chugani DC, Muzik O, Behen M, Janisse J, Rothermel R, et al.
Autism in tuberous sclerosis complex is related to both cortical and
subcortical dysfunction. Neurology. 2001;57(7):1269–77. https://doi.org/10.
1212/wnl.57.7.1269.
10. Jeste SS, Varcin KJ, Hellemann GS, Gulsrud AC, Bhatt R, Kasari C, et al.
Symptom profiles of autism spectrum disorder in tuberous sclerosis
complex. Neurology. 2016;87(8):766–72. https://doi.org/10.1212/WNL.
0000000000003002.
11. Datta AN, Hahn CD, Sahin M. Clinical presentation and diagnosis of
tuberous sclerosis complex in infancy. J Child Neurol. 2008;23(3). https://doi.
org/10.1177/0883073807309250.
12. Wortmann SB, Reimer A, Creemers JWT, Mullaart RA. Prenatal diagnosis of
cerebral lesions in Tuberous sclerosis complex (TSC). Case report and review
of the literature. Eur J Paediatr Neurol. 2008;12(2):123–6.
13. Jeste SS, Wu JY, Senturk D, Varcin K, Ko J, McCarthy B, et al. Early
developmental trajectories associated with ASD in infants with tuberous
sclerosis complex. Neurology. 2014;83(2):160–8. https://doi.org/10.1212/WNL.
0000000000000568.
14. McDonald NM, Murphy HG, Messinger DS. Empathic responding in
preschool-aged children with familial risk for autism. Autism Res. 2017;
10(10):1621–8. https://doi.org/10.1002/aur.1819.
15. Kasari C, Gulsrud A, Paparella T, Hellemann G, Berry K. Randomized
comparative efficacy study of parent-mediated interventions for toddlers
with autism. J Consult Clin Psychol. 2015;83(3):554–63. https://doi.org/10.
1037/a0039080.
16. Kasari C, Gulsrud AC, Wong C, Kwon S, Locke J. Randomized controlled
caregiver mediated joint engagement intervention for toddlers with autism.
J Autism Dev Disord. 2010;40(9):1045–56. https://doi.org/10.1007/s10803-
010-0955-5.
17. Kasari C, Lawton K, Shih W, Barker TV, Landa R, Lord C, et al. Caregiver-
Mediated Intervention for Low-Resourced Preschoolers With Autism: An
RCT. Pediatrics. 2014;134(1):e72. https://doi.org/10.1542/peds.2013-3229.
18. Shire SY, Chang YC, Shih W, Bracaglia S, Kodjoe M, Kasari C. Hybrid
implementation model of community-partnered early intervention for
toddlers with autism: a randomized trial. J Child Psychol Psychiatry. 2016;
58(5):612–22. https://doi.org/10.1111/jcpp.12672.
19. Elrod JK, Fortenberry JL Jr. The hub-and-spoke organization design: an
avenue for serving patients well. BMC Health Serv Res. 2017;17(Suppl 1):457.
https://doi.org/10.1186/s12913-017-2341-x.
20. Zhou C, Crawford A, Serhal E, Kurdyak P, Sockalingam S. The impact of
project ECHO on participant and patient outcomes: a systematic review.
Acad Med. 2016;91(10):1439–61. https://doi.org/10.1097/ACM.
0000000000001328.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Hyde et al. Journal of Neurodevelopmental Disorders            (2020) 12:3 Page 7 of 7
